MDT

89.46

+0.89%↑

VEEV

281.37

+0.23%↑

A

113.33

-1.71%↓

WBA

11.49

-0.09%↓

HQY

97.29

-0.38%↓

MDT

89.46

+0.89%↑

VEEV

281.37

+0.23%↑

A

113.33

-1.71%↓

WBA

11.49

-0.09%↓

HQY

97.29

-0.38%↓

MDT

89.46

+0.89%↑

VEEV

281.37

+0.23%↑

A

113.33

-1.71%↓

WBA

11.49

-0.09%↓

HQY

97.29

-0.38%↓

MDT

89.46

+0.89%↑

VEEV

281.37

+0.23%↑

A

113.33

-1.71%↓

WBA

11.49

-0.09%↓

HQY

97.29

-0.38%↓

MDT

89.46

+0.89%↑

VEEV

281.37

+0.23%↑

A

113.33

-1.71%↓

WBA

11.49

-0.09%↓

HQY

97.29

-0.38%↓

Search

Arcus Biosciences Inc

Abrir

SetorSaúde

9.18 1.55

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.95

Máximo

9.36

Indicadores-chave

By Trading Economics

Rendimento

-18M

-112M

Vendas

2M

28M

Margem de lucro

-400

Funcionários

627

EBITDA

-34M

-122M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+180.07% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

56M

1B

Abertura anterior

7.63

Fecho anterior

9.18

Sentimento de Notícias

By Acuity

50%

50%

154 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Neutral Evidence

Arcus Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de jul. de 2025, 23:41 UTC

Conversa de Mercado

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 de jul. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 de jul. de 2025, 23:05 UTC

Conversa de Mercado

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 de jul. de 2025, 21:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de jul. de 2025, 21:36 UTC

Conversa de Mercado

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

15 de jul. de 2025, 20:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 de jul. de 2025, 20:07 UTC

Ganhos

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 de jul. de 2025, 20:06 UTC

Conversa de Mercado

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 de jul. de 2025, 19:54 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

15 de jul. de 2025, 19:54 UTC

Conversa de Mercado

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 de jul. de 2025, 19:38 UTC

Conversa de Mercado

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 de jul. de 2025, 19:09 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 de jul. de 2025, 19:07 UTC

Conversa de Mercado

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 de jul. de 2025, 19:03 UTC

Conversa de Mercado

Gold Slips as Big Buyers Pull Back -- Market Talk

15 de jul. de 2025, 18:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 de jul. de 2025, 18:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 de jul. de 2025, 18:13 UTC

Conversa de Mercado

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 de jul. de 2025, 17:40 UTC

Conversa de Mercado

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 de jul. de 2025, 17:40 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de jul. de 2025, 17:25 UTC

Aquisições, Fusões, Aquisições de Empresas

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 de jul. de 2025, 17:24 UTC

Conversa de Mercado

Dollar Gains Strength After Inflation Data -- Market Talk

15 de jul. de 2025, 16:49 UTC

Conversa de Mercado

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Financial Services Roundup: Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

15 de jul. de 2025, 15:42 UTC

Conversa de Mercado

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Comparação entre Pares

Variação de preço

Arcus Biosciences Inc Previsão

Preço-alvo

By TipRanks

180.07% parte superior

Previsão para 12 meses

Média 25.29 USD  180.07%

Máximo 46 USD

Mínimo 12 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcus Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

8

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

8.01 / 8.75Suporte e Resistência

Curto Prazo

Neutral Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

154 / 376 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.